
Researchers Find Strange Link Between Marathon Running and Cancer
Oncologists at the Inova Schar Cancer Institute in Virginia conducted the study, which examined the colons of relatively young people who had run several long-distance races. They found these runners had a much higher rate of having potentially dangerous adenomas (a type of polyp) than would be expected for their age. Though the findings are preliminary and require more confirmation, they may point to a real connection between colorectal cancer and extreme physical activity.
'It tells us there's a signal here,' David Lieberman, a gastroenterologist and professor emeritus at Oregon Health and Science University not affiliated with the study, told the New York Times Tuesday. 'We wouldn't have expected these rates of high-risk adenomas, which are cancer precursor lesions, in an age group like this.'
Lead researcher Timothy Cannon was inspired to perform the study after he treated three young patients with colorectal cancer, all of whom had run ultramarathons (defined as any race longer than 26.2 miles). Not only were his patients fit, but they were also much younger than the typical case, the oldest being 40.
In 2022, Cannon and his colleagues began recruiting endurance athletes for their prospective study. The volunteers had all run at least two ultramarathons or five regular marathons; they also had no family history of colorectal cancer or other apparent risk factors. All told, 100 athletes between the ages of 35 and 50 took part and were given colonoscopies.
People Who Are More Flexible Tend to Live Longer, Study Finds
The researchers went looking for advanced adenomas in the colons of their volunteers, relatively large or otherwise unusual polyps. Though these growths are themselves benign, they have a higher risk of turning cancerous than other polyps. Then they compared the rate of finding these polyps in their athletes to historical trends.
About 1.2% of people in their 40s at average risk for colorectal cancer would be expected to have advanced adenomas, according to the researchers. By sharp contrast, 15% of the runners they studied had them, while nearly half had polyps in general.
'Consideration of refined screening strategies for this population is warranted,' the researchers wrote in their study.
The team presented its results earlier this year at the annual conference of the American Society of Clinical Oncology. That means this study hasn't yet undergone the formal peer-review process. The authors are also quick to note their work isn't definitive proof that endurance running can cause colorectal cancer.
Assuming this link is causative, there remains the burning question of why. As even weekend 5k joggers will know, running can occasionally trigger bouts of gastrointestinal distress (the namesake runner's diarrhea). These injuries are sometimes caused by temporarily restricted blood flow to the intestines that damages nearby cells. It's possible, the researchers speculate, that extreme runners who regularly experience this blood flow loss can develop the sort of chronic inflammation that makes cancer more likely to emerge.
Being a Couch Potato Is Bad for Your Memory, Study Warns
At this point, though, that's only one hypothesis for what may be happening here. The researchers say future studies should try to confirm their findings as well as untangle the causes and risk factors that could explain this potential higher risk.
All that said, this research shouldn't scare anyone away from running or any other form of cardio. The many health benefits of regular physical activity—which importantly include a lower risk of at least eight different types of cancer—still far outweigh the risks for the average person.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims
Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy. Unsold completed new-build inventory is so high this $34B homebuilder is turning to investors 'Job hugging' is the newest career trend: Here's what it means—and why Gen Z is into it Spotify just redesigned the way you'll 'listen' to audiobooks According to a press release posted early on August 18, GoodRx has struck a deal with the pharmaceutical giant Novo Nordisk to sell its popular semaglutide medications, Ozempic and Wegovy, for just $499 per month to 'eligible self-paying customers.' GoodRx doesn't sell or dispense any drugs itself, but rather provides savings and coupons that can be applied in pharmacies. Its exclusive Ozempic and Wegovy offerings, available starting today, are the lowest out-of-pocket costs for the medications available on the market. The news comes just weeks after Novo Nordisk cut ties with the telehealth company Hims & Hers Health (NYSE: HIMS) over claims that Hims & Hers was selling 'knockoff' versions of Wegovy. It's a dispute that reflects a broader discussion around whether compounded semaglutide drugs—or non-FDA approved versions of brand-name medicines—are a violation of intellectual property laws. As of this writing, GoodRx's stock is up by more than 30% since market close. Here's what to know about Novo Nordisk's latest partnership and its ongoing legal battles against compounded GLP-1s. GoodRx's collaboration with Novo Nordisk In the last year alone, GoodRx reports that nearly 17 million people visited the site searching for information and savings on GLP-1 medications—a 22% increase from the previous year. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' Wendy Barnes, GoodRX president and CEO, said in the press release. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them.' In the past, a spokesperson told Fast Company, GoodRx has worked with both Novo Nordisk and its competitor Eli Lilly to offer commercially insured patients manufacturer savings cards on GLP-1s. The company has also offered savings on other types of weight loss/diabetes treatments, including Contrave, Dexcom G7, Lantus, and Qsymia. However, this is the first time that GoodRx has offered a cash price for a GLP-1. The $499 monthly self-pay cost will be available at more than 70,000 retail locations nationwide. Novo Nordisk's current legal battles over compounded GLP-1s So far, investors' response to GoodRx's new collaboration has been overwhelmingly positive. It stands in sharp contrast to Hims & Hers' recent breakup with Novo Nordisk, which caused the telehealth company's share prices to plummet in late June. Hims & Hers and Novo Nordisk parted ways over Hims & Hers' offering of compounded versions of Wegovy. Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand-name drugs using their active ingredient, semaglutide, and sell them at a lower cost. However, Hims & Hers has continued to sell its compounded version of Wegovy long after the FDA lifted the shortage back in February. Now, Novo Nordisk is arguing that these compounded drugs are both a violation of its intellectual property and potentially dangerous to patients, due to their lack of FDA approval. Early this month, Novo Nordisk announced 14 new lawsuits against small pharmacies, telehealth providers, and weight-loss clinics over compounded versions of Ozempic and Wegovy—bringing its total cases filed on the matter up to more than 130 in 40 states. Experts say that federal compounding laws are just vague enough to allow for various interpretations, meaning that Novo Nordisk's current legal challenges could shape the way courts interpret those boundaries in the future. In a statement to Yahoo Finance, Barnes offered a clear look into GoodRx's stance on compounded drugs: 'There's no question we could have tried to do something sooner from a compounded alternative pathway, but we have been very clear in our belief that it needed to be FDA-approved, lawfully approved. It just wasn't a pathway that we were going to support,' she said. This post originally appeared at to get the Fast Company newsletter:
Yahoo
32 minutes ago
- Yahoo
Walmart recalls shrimp possibly exposed to radioactive material
Walmart has recalled some shrimp products in 13 US states after one shipment of seafood tested positive for radioactive contamination. The US Food and Drug Administration said varieties of frozen shrimp sold under Walmart's Great Value label could have been exposed to a dangerous isotope in shipping containers. One sample of breaded shrimp tested positive for the substance, but this positive sample "did not enter US commerce", the FDA said. Consumers are advised to throw away recently bought Walmart shrimp that matches this description - and not to eat or serve it. "The health and safety of our customers is always a top priority," a Walmart spokesperson told the BBC. "We have issued a sales restriction and removed this product from our impacted stores. We are working with the supplier to investigate." The spokesperson added that consumers who bought the recalled products can visit any Walmart location for a full refund. The recalled shrimp was sold at Walmart locations in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, and shoppers in those states were advised to be cautious. It came from an Indonesian supplier that has since had multiple shipping containers denied entry to the US, the FDA said. One shipment tested positive for Cesium-137, the radioactive form of the chemical element Cesium. The amount contained in the tested shipment held by the FDA was not enough to pose acute harm to consumers, but exposure over time could pose an elevated risk of cancer by damaging living cells in the body, said FDA officials.
Yahoo
32 minutes ago
- Yahoo
RFK Jr. attacks pediatricians' group over vaccine recommendations
The gloves are off in Robert F. Kennedy Jr.'s feud with American doctors. Hours after the American Academy of Pediatrics, the professional society for doctors who care for children, issued Covid-19 vaccine guidance contradicting that of the health secretary, Kennedy accused the group of engaging in a 'pay-to-play scheme to promote commercial ambitions of AAP's Big Pharma benefactors' in a post on social media platform X. Kennedy cited donations from Covid mRNA vaccine drugmakers Pfizer and Moderna, among other pharmaceutical companies, to the pediatricians' Friends of Children Fund, which backs projects promoting children's health and health equity. Kennedy said the contributions constituted a conflict of interest and suggested they led to the group's decision to recommend that young children, between 6 and 23 months old, receive Covid vaccines. In May, the Centers for Disease Control and Prevention dropped its recommendation that all children 6 months and older get Covid shots. Kennedy at the time said the move was based on 'common sense' and 'good science.' The AAP, however, said it had retained its guidance for young children to get the shots because they are still at risk of severe cases of the disease. 'COVID-19 continues to result in hospitalization and death in the pediatric population,' the group said in a release explaining its recommendations, adding that 'children younger than 2 years old are especially vulnerable to severe COVID-19 and should be prioritized for vaccination.' The pediatric group did not immediately respond to POLITICO's request for comment regarding Kennedy's remarks. Earlier Tuesday, HHS spokesperson Andrew Nixon accused the pediatricians of 'freelancing its own recommendations, while smearing those who demand accountability' in a statement to POLITICO. AAP President Susan J. Kressly defended her group's guidance in response, saying they were 'based only in the science, the needs of children, and the care that pediatricians have for the children in every community.' Despite the disagreement over vaccination of young children, both the new CDC guidance and the pediatricians continue to recommend shots for children with underlying conditions that could put them at risk for severe disease. Both have also scaled back recommendations for healthy children older than 6 months, saying that parents of children without underlying conditions should decide on vaccination in consultation with their pediatrician. Why it matters: The pediatricians' split with the CDC underscores the depth of the distrust between the medical establishment and Kennedy — a longtime vaccine skeptic who once said the Covid vaccine was 'the deadliest vaccine ever made' in defiance of scientific consensus. Before Kennedy's arrival, the agency and the pediatricians agreed on vaccine recommendations, but Kennedy's efforts to overhaul federal vaccine policy have upset the relationship. Earlier this summer, he ousted all the members of the expert panel that advises the CDC on vaccines, the Advisory Committee on Immunization Practices, tapping new members with a history of vaccine skepticism. Most recently, Kennedy rescinded $500 million earmarked for research into mRNA technology, which was used to develop the Moderna and Pfizer Covid vaccines. And his latest post isn't the first time he's criticized doctors. The May report from his Make America Health Again Commission assessing the causes of chronic disease in children was laced with accusations that doctors are influenced by the pharmaceutical industry to overprescribe certain medications and fail to treat the root causes of disease. The split also comes as children return to school and the annual fall vaccination campaign for Covid and the flu is beginning. Kennedy suggested that the pediatric group could be exposing its member doctors to liability in his X post, stating that 'AAP should also be candid with doctors and hospitals that recommendations that diverge from the CDC's official list are not shielded from liability under the 1986 Vaccine Injury Act.' The National Vaccine Injury Compensation Program, which that law created, doesn't cover Covid vaccines, but Kennedy has said he wants to overhaul the system for compensating people who experience serious side effects from vaccines. He would likely need Congress' assent to change it.



